Clinical trial · Observational
Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents
A Healthcare Cost and Resource Utilization Analysis of Intravenous and Oral Agents in the Treatment of Metastatic Renal Cell Carcinoma
NCT02928263CI-TRIAL-00028647withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Business objectives have changed
Summary
Brief summary (as posted)
A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients treated with IV agents
- description
- Metastatic renal cell carcinoma patients treated with IV agents
- interventionNames
- Other: Non-Interventional
- label
- Patients treated with oral agents
- description
- Metastatic renal cell carcinoma patients treated with oral agents
- interventionNames
- Other: Non-Interventional
Primary outcomes (4)
- measure
- Distribution of Healthcare costs for patients treated with oral drugs used in the first-line treatment of Metastatic renal cell carcinoma (mRCC)
- timeFrame
- Up to 63 months
- description
- All-cause healthcare costs will be calculated in the first-line oral cohort as per-patient-per-month (PPPM) costs.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Diagnosis with metastatic renal cell carcinoma * Prescription/administration of one of the IV or oral agents examined in the study Exclusion Criteria: * Patients with other primary cancer diagnosis before RCC diagnosis * Patients with pregnancy or HIV/AIDS
References
Publications (0)
Data not yet available
No reference posted for this study.